All articles by Swagath Bandhakavi
Swagath Bandhakavi
FDA approves Genentech’s Itovebi for advanced breast cancer with PIK3CA mutation
In the INAVO120 study, Itovebi reduced the risk of disease progression or death by 57% when combined with palbociclib and fulvestrant, compared to using palbociclib and fulvestrant alone
Sanofi in talks with CD&R for sale of controlling stake in Opella
Opella, headquartered in France, operates within the consumer healthcare sector in 100 countries
Johnson & Johnson submits application to the EMA for Darzalex SC-based quadruplet regimen for newly diagnosed multiple myeloma patients
Submission supported by data from the Phase 3 CEPHEUS study for the treatment of patients with newly diagnosed multiple myeloma for whom transplant is not planned as initial therapy
Roche says positive Phase III results show Xofluza significantly reduces the transmission of influenza viruses
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household members
PharmaJet and Scancell partner on needle-free DNA vaccine for melanoma
Under the agreement, Scancell will utilise the Stratis system for both clinical development and future commercialisation of its melanoma DNA vaccine
BeiGene’s Tevimbra gets Israeli approval for oesophageal squamous cell carcinoma
The approval makes Tevimbra available as a monotherapy for those suffering from the disease
Nura Bio closes Series A financing with $68m in new funds
Company announces successful completion of Phase 1 study of NB-4746, Nura Bio’s brain-penetrant SARM1 inhibitor
Debiopharm partners with WhiteLab Genomics to enhance drug targeting in oncology
Debiopharm will utilise WhiteLab Genomics’ AI platform to identify agents that boost the targeting capabilities of non-viral vectors in oncology
FDA grants RMAT status to Poseida’s P-BCMA-ALLO1 for relapsed/refractory multiple myeloma
P-BCMA-ALLO1 is an investigational allogeneic CAR-T cell therapy that is presently in Phase 1/1b clinical trials
Novartis’ Kisqali reduces risk of recurrence by 28.5% in broad population of patients with early breast cancer
Invasive disease-free survival benefit continued to increase after completion of the three-year treatment period across all patient subgroups, including those with node-negative disease